BioMAP T Cell Autoimmune Panel

The T Cell Autoimmune Panel includes BioMAP systems comprised of complex co-cultures of immune and adherent human primary cell types. These cell-based assay systems model adaptive immune cell microenvironment and T and B cell responses in a platform amenable to compound screening. With the BioMAP T Cell Autoimmune Panel, you can obtain quantitative measures of test agent impact on transitional biomarker readouts (proteins, chemokines, cytokines, cell surface receptors and measures of cell health) appropriate for investigations of rheumatoid arthritis, psoriasis, conditions of chronic inflammation, autoimmune disease, and hematological oncology.

Applications for Drug Discovery with Human-centric BioMAP T Cell Autoimmune Panel

• Benchmark to seven standard-of-care reference drugs
• Identify translational biomarkers in clinically relevant disease models
• Gain insights on indication selection and efficacy, as well as early dosing guidance
• Obtain tissue-specific data within one assay panel, in systems that model the context of stromal tissue, vascular endothelium, and the germinal centers of secondary lymphoid organs

The BioMAP T Cell Autoimmune Panel distinguishes cytotoxicity, antiproliferative, immune inhibitory, inflammatory, and tissue remodeling responses in cell-based, disease-relevant, biological systems. These systems preserve key signaling networks of the T and B-cell adaptive immune response.

Impact of Crisaborole on Biomarkers in Systems Modeling the Adaptive Immune Response

Figure 1. Assessment of the small molecule crisaborole, a phosphodiesterase 4 (PDE-4) inhibitor, in the BioMAP T Cell Autoimmune Panel, identifies concentration-dependent effects on biomarkers representing immunomodulation, inflammation, and tissue remodeling responses.
 
Crisaborole is not cytotoxic at the concentrations tested in this study, near the clinically relevant concentration (Cmax in the range of 125 ng/ml). At 10 μM, it is antiproliferative to human primary B cells and T cells (grey arrows). Of the 51 cytokine, chemokine, cell surface receptor, and cell health measures quantified in the BioMAP T Cell Autoimmune Panel, crisaborole influenced statistically significant changes in 29, including key inflammation-related activities (decreased E-selectin, VCAM-1, MCP-1, sTNFα, MIG, IP-10, IL-8; increased P-selectin), immunomodulatory activities (decreased CD40, sIgG, sIL-10, sIL-17A, CD38, sIL-17F, CD69, sIL-2; modulated sIL-6), and tissue remodeling activities (decreased sTGFβ; increased sVEGF). Tested concentrations of crisaborole are indicated.

Heatmap Visualization to Compare Crisaborole to Standards of Care

Figure 2. Distinct outcomes of crisaborole treatment, compared to seven standard-of-care drugs, include increased sVEGF in the HDFSAg system modeling responses in stromal tissue, IL-6 in the BT system modeling secondary lymphoid tissue, and E-Selectin in the SAg system modeling vascular endothelium. Heatmap visualization of biomarker changes with modulated biomarkers in orange if protein levels are increased (log10 ratio > 0.1 and p-value < 0.01), blue if protein levels are decreased (log10 ratio < -0.1 and p-value < 0.01), and white if unchanged.

Available Systems & Readouts